- Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status
SEOUL, South Korea,
Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of a significant study at the European Society for Medical Oncology (ESMO) Congress 2024 in
Barcelona, Spain, from
September 13-17.
Already have an active account? Log in
here.
Continue reading with one of these options:
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
If you have an active account, log in
here
.
